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ABSTRACT
Approximately half of the colorectal cancer (CRC) patients develop metastatic 
disease. Fluoropyrimidine-based chemotherapy forms the backbone of treatment in 
these patients. However, the response to this therapy varies between individuals. 
Therefore, an important challenge in CRC research is to identify biomarkers that are 
predictive of this response. In this study, we explored the potential of miRNAs, and 
the miRNA producing protein Dicer, as biomarkers that can predict chemo-sensitivity 
to fluoropyrimidine chemotherapy in patients with metastatic colorectal cancer 
(mCRC). We analyzed the levels of 22 miRNAs and the Dicer protein in primary tumors 
from patients with mCRC who were treated with first-line capecitabine monotherapy 
within the CAIRO trial of the Dutch Colorectal Cancer Group. Correlation between 
the expression status of miRNAs or Dicer in primary tumors and the progression free 
survival (PFS) were investigated. Patients with low expression of miR-143 in their 
primary tumor had increased median PFS compared to those with high expression 
of miR-143. Furthermore, FXYD3, an ion transport regulator and a putative target of 
miR-143, also showed an association with PFS. These findings warrant further studies 
to investigate the relationship between miR-143, FXYD3 and fluoropyrimidines, and 
the clinical utility of miR-143 as biomarker.
INTRODUCTION
Colorectal cancer (CRC) is worldwide one of the 
most common types of cancer, and a leading cause of 
cancer death for both men and women (http://globocan.
iarc.fr). Approximately half of the CRC patients develop 
metastatic disease, either at diagnosis or during follow-
up [1]. For over 40 years fluoropyrimidine-based 
chemotherapy (5-fluorouracil, capecitabine) has been used 
in the treatment of patients with metastatic CRC (mCRC), 
and significantly prolongs survival [2]. However, not all 
patients respond to treatment [3]. Moreover, chemotherapy 
is associated with toxicity. Therefore, biomarkers that can 
differentiate patients into responders and non-responders 
would optimize health care.
Much effort has already been put into the 
development of molecular markers predicting the response 
to fluoropyrimidine-based chemotherapy. Thymidylate 
synthase (TS) is possibly the most extensively studied 
biomarker in this context. However, for the metastatic 
setting none of the studied markers is ready for 
implementation in daily clinical practice [4].
MicroRNAs (miRNAs) are non-coding RNAs that 
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inhibit gene expression post-transcriptionally. They are 
encoded within the genome and are initially transcribed 
as large primary transcripts (several kilobases) by RNA 
polymerase II. Two RNase III enzymes successively 
cleave the primary transcripts, Drosha in the nucleus and 
Dicer in the cytoplasm. Ultimately, a 22 nt long single-
stranded mature miRNA is incorporated into the multi-
protein RNA-induced silencing complex (RISC), which 
as a whole binds to the 3’ untranslated region of a target 
messenger RNA (mRNA). Imperfect binding to target 
mRNA represses its translation, whereas perfect binding 
leads to cleavage and degradation of the target mRNA [5].
MiRNAs influence basic biological processes 
such as growth, invasion, proliferation, differentiation, 
angiogenesis and cell death. The effect of one specific 
miRNA can be widespread, since it can potentially 
modulate hundreds of different downstream genes. Altered 
miRNA levels are implicated in early tumorigenesis 
as well as disease progression. Moreover, there are 
indications that they can affect chemo-sensitivity of cancer 
cells [6-13]. In combination with their remarkable stability 
that allows detection in formalin-fixed, paraffin-embedded 
(FFPE) material [14], miRNAs are molecules that could 
serve as biomarkers for chemotherapy.
This study was designed to identify a predictive 
factor for the response to fluoropyrimidine chemotherapy 
in patients with mCRC, focusing at the miRNA pathway. 
More specifically, we analyzed the expression of Dicer and 
22 miRNAs that were shown to be associated with CRC.
RESULTS
Assessment of associations between Dicer and 
survival
Immunohistochemical (IHC) analysis was 
performed to study the influence of Dicer expression on 
progression free survival (PFS) of mCRC patients who 
received fluoropyrimidine-based chemotherapy. Of the 
243 analyzed tumors (Supplemental Table 1 contains the 
baseline characteristics of the patients and tumors), only 
six tumors showed strong Dicer staining (IHC 3), whereas 
most (n = 154) showed a weak staining (IHC 1) (Figure 
1A). Survival analysis for this study population did not 
show a significant association between PFS and Dicer 
staining (Figure 1B).
Comparison of miRNA expression in primary 
tumors and matched normal tissue
We next investigated the predictive potential 
of miRNAs for patients with mCRC who received 
fluoropyrimidine-based chemotherapy. The miRNAs were 
selected based on literature research for studies linking 
miRNAs to (fluoropyrimidine-based) chemotherapy 
and/or CRC. In total, we analyzed the mature miRNA 
levels of 22 miRNA using stem-loop quantitative reverse 
transcriptase-polymerase chain reaction (Supplemental 
Table 4). 
For 55 patients we assessed the relative miRNA 
levels in tumor and normal tissue. For five miRNAs 
(miR34a, miR-93, miR-19b, miR-92a, miR125b) no 
significant difference between expression in tumor and 
normal tissue was observed (P > 0.05), for the others there 
was a significant difference (Table 1). Especially, miR-31 
and miR-21 showed a higher median expression in tumor 
tissue, and miR-137 and miR-215 showed lower median 
expression in tumor compared to normal tissue (Table 1 
and Figure 2). 
Evaluation of correlations between Dicer staining 
and miRNA levels
For 43 patients we collected both IHC for Dicer 
as well as miRNA expression data (Figure 3A). We used 
this to investigate if the Dicer staining correlated with the 
miRNA expression level data. We compared tumors with 
and without staining for Dicer (IHC 0 = 4; IHC 1+2+3 = 
39 (Figure 3B). Only, miR-21 and miR-26b showed the 
expected positive correlation between Dicer expression 
and miRNA level (Figure 3C). 
MiR-143 is a putative predictive biomarker
To determine whether any of the 22 miRNAs were 
associated with PFS, the patients were sub-divided based 
on the median expression of the miRNA in the tumor 
tissues, Kaplan-Meier curves were made, log-rank test 
performed, and we adjusted for multiple testing. This 
approach showed in particular a significant difference for 
miR-143 (Table 2). The median PFS of the sub-groups 
(median PFS for low expression = 9 months (95%CI: 
7-11); median PFS for high expression = 5 months 
(95%CI: 4-8)) and the Kaplan-Meier curves suggest that 
low miR-143 expression in tumor tissue is associated with 
increased PFS (adjusted p-value = 0.012, Figure 4A). 
There was no significant difference observed for OS, but 
when looking at response, as defined based on RECIST 
criteria, there was also a significant difference, with more 
response in the sub-group with low miR-143 expression 
(p-value = 0.037, Figure 4B). We subsequently checked if 
other clinico-pathological characteristics could play a role 
as confounders. We observed that, in the sub-group with 
low miR-143 expression and increased PFS, the median 
age of the patients at diagnosis was somewhat higher 
and that the number of cycles of capecitabine that were 
administered was higher (Supplemental Table 2 and Figure 
4C). Finally, in multivariate Cox regression analysis (using 
only the variables that showed a significant difference in 
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Table 1: Comparison of the miRNA expression in tumor and normal mucosa.
Expression analysis: normal vs tumor







1 miR-16 0.709 1.363 0.520 3.58E-10 4.87E-09  
2 miR-18a 0.047 0.035 1.361 7.23E-04 9.94E-04  
3 miR-19b 4.032 3.963 1.017 6.78E-01 7.46E-01 *
4 miR-21 5.574 2.779 2.005 8.85E-10 4.87E-09  
5 miR-26b 0.137 0.314 0.437 5.49E-10 4.87E-09  
6 miR-31 0.348 0.033 10.432 1.45E-04 2.13E-04  
7 miR-34a 0.257 0.198 1.297 5.66E-02 6.92E-02 *
8 miR-92a 0.454 0.400 1.134 7.34E-01 7.69E-01 *
9 miR-93 0.262 0.313 0.838 1.71E-01 1.98E-01 *
10 miR-103 0.136 0.229 0.593 2.24E-08 5.47E-08  
11 miR-125b 0.376 0.419 0.897 9.30E-01 9.30E-01 *
12 miR-137 0.000 0.002 0.181 2.13E-08 5.47E-08  
13 miR-140 0.116 0.182 0.635 6.31E-05 1.07E-04  
14 miR-143 1.853 3.509 0.528 1.22E-04 1.92E-04  
15 miR-145 9.010 26.988 0.334 6.06E-07 1.21E-06  
16 miR-148a 0.076 0.118 0.643 3.79E-03 4.91E-03  
17 miR-191 0.757 1.553 0.488 2.04E-09 6.40E-09  
18 miR-192 1.197 3.882 0.308 1.42E-09 5.77E-09  
19 miR-215 0.882 5.849 0.151 8.85E-10 4.87E-09  
20 miR-222 0.812 1.251 0.649 5.68E-05 1.04E-04  
21 let7a 0.449 0.869 0.516 2.00E-07 4.41E-07  
22 let7g 0.283 0.550 0.514 1.57E-09 5.77E-09  
*Indicates > 0.05
Figure 1: Dicer expression in the primary tumors of patients with mCRC and the related PFS. A. Variable Dicer staining 
intensities were observed (IHC0-3). The number of patients per category of Dicer staining are depicted in a bar plot. B. Kaplan-Meier 
survival analysis comparing CRC patients with different Dicer staining intensities in the tumor. No significant association between PFS and 
Dicer staining was observed.
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Table 2: Comparison of the survival distributions of patients sub-grouped based on miRNA expression.
Survival analysis: PFS for patients with low vs high miRNA expressing tumors
 miRNA p-value Log-rank test adjusted p-value Log-rank test
1 miR-16 0.095 0.249
2 miR-18a 0.524 0.576
3 miR-19b 0.468 0.544
4 miR-21 0.329 0.483
5 miR-26b 0.995 0.995
6 miR-31 0.276 0.433
7 miR-34a 0.196 0.376
8 miR-92a 0.040 0.219
9 miR-93 0.023 0.168
10 miR-103 0.160 0.351
11 miR-125b 0.055 0.219
12 miR-137 0.060 0.219
13 miR-140 0.856 0.897
14 miR-143 0.001 0.012
15 miR-145 0.100 0.249
16 miR-148a 0.390 0.536
17 miR-191 0.205 0.376
18 miR-192 0.102 0.249
19 miR-215 0.009 0.095
20 miR-222 0.470 0.544
21 miR-let7a 0.464 0.544
22 miR-let7g 0.244 0.413
Figure 2: MiRNA expression in CRC tumors (T) compared to normal (N) mucosa. Box plots for four exemplary miRNAs 
displaying differences between the expression in tumor and normal mucosa. A. miR-31 and miR-21 showed a higher median expression in 
the tumor. B. miR-137 and miR-215 showed lower median expression in the tumor.
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univariate analysis) miR-143 expression was the strongest 
predictor of PFS (Figure 4D).
Prediction of target genes
One miRNA can regulate many different target 
genes, and in principle a small change in miRNA level 
could have a large biological effect. To get insight in how 
miR-143 and sensitivity to fluoropyrimidines are linked, 
two web-based prediction algorithms were used to identify 
putative target genes. Both computations generated a 
substantial list of candidates (Material and methods, 
Supplemental Table 5 and 6).
In addition, TCGA miRNA-seq and RNA-seq data 
were analyzed to select putative target genes. We assumed 
that miR-143 degrades its target mRNAs, and selected 
those genes that showed a negative correlation with miR-
143 expression (Supplemental Table 7).
Next, overlaps between the gene lists obtained with 
the different approaches were determined. Thirty-four 
genes were common in the lists obtained with the target 
prediction algorithms (Figure 5A). From this overlap 
the gene FXYD3 was the only gene that also showed 
a negative correlation. This is a protein that belongs to 
a small family of proteins that can regulate sodium-
potassium pumps, with one possible binding site of miR-
Figure 3: Evaluation of correlations between Dicer staining and miRNA levels. A. Heat map indicating the correlation 
between Dicer expression and miRNA level. Positive correlations are black; negative correlations are white. Small p-values are in red; 
p-values above 0.05 are in pink. B. miR-21 and miR-26b showed higher expression in the samples with Dicer expression compared to 
those without.
Oncotarget23001www.impactjournals.com/oncotarget
143 in its 3’ UTR (Figure 5B).
Expression of FXYD3
IHC analysis was performed to check if FXYD3 
expression correlated with the miR-143 expression, and 
to study the influence of FXYD3 expression on PFS of 
mCRC patients who received fluoropyrimidine-based 
chemotherapy. We observed cytoplasm, membrane 
and nuclear staining. In the cytoplasm weak and strong 
staining was distinguished (Figure 6A).
The same 243 patients were analyzed as for the Dicer 
protein. Unfortunately, we could not properly analyze the 
correlation between FXYD3 and miR-143 expression, 
because only very few tumors showed the weak staining. 
Figure 4: MiR-143 expression is associated with PFS. A. Survival curves for patients with low and high miR-143 expression in 
their primary tumor (log rank test adjusted p-value = 0.012). High expression of miR-143 was also associated with a shorter PFS. B. Bar 
graphs for patients with low and high miR-143 expression in their primary tumor showing the proportions of response to therapy evaluated 
according to the RECIST criteria (fisher test p-value = 0.037). Complete response (CR); partial response (PR); no change/stable disease 
(SD.; progressive disease (PD.. The proportions of patients that experienced response to therapy (CR or PR) were higher for patients with 
primary tumors with low miR-143 expression levels as compared to primary tumors with high miR-143 expression levels. C. Distribution 
of other variables in the two sub-groups based on miR-143 expression. Left: distributions of the number of cycles of capecitabine that were 
administered to the patients (Kruskal-Wallis test p-value = 0.012). Right: distributions of the age (in years) of the patients at diagnosis 
(Kruskal-Wallis test p-value = 0.007). D. Table showing the results of the multivariate Cox regression analysis. MiR-143 expression is the 
strongest independent predictors of PFS.
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Figure 5: FXYD3 is putative target of miR-143. The web-based prediction algorithms MicroCosm and TargetScan were used to 
identify putative miR-143 target genes. A. Venn diagram depicting the number of overlapping and unique genes. B. Possible binding site 
of miR-143 in the 3’ UTR of FXYD3.
Figure 6: FXYD3 expression in the primary tumors of patients with mCRC and the related PFS. A. Two different tumor 
samples with different cytoplasmic staining intensity for FXYD3 (weak vs strong). B. Two patient sub-groups based on FXYD3 expression. 
Left: the number of patients per staining category. The majority of the samples showed strong staining. Right: Kaplan-Meier survival 
analysis comparing patients with weak and strong staining. A significant association between PFS and FXYD3 was observed.
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Among the 43 patients for which we collected both IHC 
for FXYD3 and miR-143 expression data there were only 
2 tumors with low FXYD3 expression in the cytoplasm 
compared to 41 tumors with high FXYD3 expression.
Of all tumors with IHC for FXYD3, 32 tumors 
showed weak, whereas 211 showed a strong cytoplasmic 
staining (Figure 6B). Interestingly, survival analysis 
showed a significant association between PFS and FXYD3 
staining in the cytoplasm (Figure 6B). The median PFS 
for patients with weak and strong staining was 4 months 
(95%CI: 2-6) and 6 months (95%CI: 6-7), respectively. 
Thus, for FXYD3 higher expression appears associated 
with increased PFS, which is as expected, opposite to the 
results for miR-143.
Next, we checked if other clinico-pathological 
features could play a role as confounders. For all of the 
analyzed characteristics there was no significant difference 
between the sub-groups with FXYD3 weak and strong 
staining, except for histology and differentiation grade of 
the primary tumor. Of the 32 tumors with FXYD3 weak 
staining, there were two tumors that were classified as 
undifferentiated carcinoma, whereas there was no tumor 
with this classification in the 211 tumors with strong 
staining (Supplementary Table 3). Multivariate Cox 
regression analysis showed that both FXYD3 staining and 
differentiation grade were independent predictors for PFS 
(HR 1.51; 95%CI 1.03-2.21 and HR 1.08; 95%CI 1.02-
1.15, respectively).
DISCUSSION
A biomarker that allows stratifying patients into 
a sub-group that will respond and a subgroup that most 
likely does not benefit from the therapy, will contribute 
to personalized medicine. In this tissue-based study we 
have tested Dicer and several relevant miRNAs for their 
predictive value for the response to fluoropyrimidine-
based chemotherapy in patients with mCRC. Among 
the selected patients we found that miR-143 could be 
used to identify a sub-group that had more benefit from 
fluoropyrimidine treatment.
Dicer expression, and its association to overall 
survival, was already studied in several CRC patient 
populations. For patients with stage II CRC, low Dicer 
expression was shown to be associated with improved 
survival [15]. In addition, for a group of patients with 
mCRC, low Dicer expression was also associated with 
better survival [16]. In contrast, in a study with primary 
tumors of all stages no relationship between Dicer 
expression and survival was found [17]. Similar to 
the other studies, we observed variable levels of Dicer 
expression in CRC. However, the Dicer expression could 
not be linked to PFS of patients with mCRC treated with 
fluoropyrimidine-based chemotherapy.
Furthermore, even though Dicer is a central enzyme 
in miRNA processing, in this study there was no clear 
correlation between miRNA and Dicer expression for 
most miRNAs. In the study by Stratmann et al (2011), 
who used qPCR to measure Dicer levels, there was only 
a positive correlation between Dicer expression and 
miRNA expression for one out of four miRNAs [17]. 
An explanation could be that, even though Dicer was 
not detected, there was still a low level of Dicer that can 
maintain the miRNA levels. On the other hand, it is also 
likely that more factors are involved in the biogenesis 
and maintenance of miRNA levels. For example, in 
zebrafish and mice Argonaute2, instead of Dicer, processes 
miRNA-451 [18, 19].
We observed for 17 out of 22 miRNAs a significant 
difference in expression between tumor and normal 
tissue (Table 1). Our data is consistent with published 
studies, in particular for miR-21 [18,39], miR-137 
[41,42] and miR-18a [40]. The main aim of this study 
was to identify predictive markers for the response to 
fluoropyrimidine-based therapy in patients. Reports on 
cell line experiments and sometimes xenografts suggested 
that expression of miRNAs influences therapeutic efficacy 
of 5-fluorouracil, but patient data were generally lacking. 
Per miRNA, the association between expression level 
and PFS was assessed. For most miRNAs we did not 
observe a significant relationship. This could be in part 
because the analyzed sample set was too small and/
or too homogeneous with relatively good prognostic 
characteristics.
For miR-143 we observed a significant association 
between its expression level and PFS. The group with 
low miR-143 expression showed longer PFS, suggesting 
higher sensitivity to capecitabine. Multivariate analysis 
also indicated that miR-143 could be a strong independent 
marker for response to capecitabine. In contrast, Borralho 
et al (2009) showed that over-expression of miR-143 
in the colorectal cell line HCT116 resulted in increased 
sensitivity to 5-fluorouracil [20]. This does not fit with 
what we observed. However, since miR-143 targets many 
genes that each have their own transcriptional regulation, 
it could be that the function of miR-143 differs under 
different circumstances (e.g. in vivo vs in vitro; early vs 
late tumor stage; 5-fluorouracil vs capecitabine).
In an attempt to explain the link between miR-143 
down-regulation and increased PFS, putative target genes 
were identified. The two web-based prediction algorithms 
both gave long lists of genes, but shared relatively few 
genes. In addition, we searched in data obtained from the 
TCGA portal for negative correlations between miR-143 
and mRNAs. Without further research, it is not clear which 
list contains the true targets of miRNA-143.
The only gene present in all three lists of putative 
target genes was FXYD3/MAT8. FXYD3 has one site in 
its 3’ UTR were hybridization of miR-143 is predicted. In 
several cancer types expression of FXYD3 appears to be 
deregulated [21-27]. Strikingly, FXYD3 is transcriptionally 
activated by 5-fluorouracil treatment in the colon cancer 
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cell line H630 [28]. If miR-143 negatively regulates 
FXYD3 expression then it is expected that low expression 
of FXYD3 is associated with worse PFS. This is indeed 
what we observed with the IHC analysis.
FXYD3 is a member of the small FXYD protein 
family. Each member is a small trans-membrane protein 
that has the short signature motif PFXYD (Pro, Phe, X, 
Tyr, Asp). It was shown that the FXYD proteins associate 
with the Na-K-ATPase (also known as sodium-potassium 
pump), which maintains the Na+ and K+ gradients across 
the plasma membrane. The FXYD proteins modulate the 
transport properties of the Na-K-ATPase [29, 30]. The 
Na+ and K+ gradient is essential in preservation of cell 
volume and the membrane potential. In addition, the Na+ 
gradient provides the energy for the activity of secondary 
transporters that transport numerous solutes, including 
other ions, glucose, and amino acids [31]. With this in 
mind it is conceivable that FXYD3 indirectly affects 
(nucleoside or nucleobase) transporters that are involved 
in the uptake of fluoropyrimidines (or metabolites of 
fluoropyrimidines), and that variations in expression of 
FXYD3 might lead to altered transport and could manifest 
as differences in cytotoxicity or response.
In summary, in this study we observe a relationship 
between miR-143 expression and PFS. Further pre-
clinical studies are now necessary for the validation 
of miR-143 as predictive marker of the response to 
fluoropyrimidine-based chemotherapy in mCRC patients. 
In addition, investigation of the target genes of miR-143, 
and in particular FXYD3, will be useful to elucidate how 
fluoropyrimidines and miR-143 are connected.
MATERIALS AND METHODS
Patient selection
The patients included in this study participated in 
the CAIRO study (ClinTrials.gov NCT00312000) of 
the Dutch Colorectal Cancer Group (DCCG) [3]. In this 
multicenter phase III study, 820 patients with advanced 
CRC were randomized between sequential (Arm A) 
and combination (Arm B) treatment with capecitabine, 
irinotecan and oxaliplatin. The primary end point of the 
study was overall survival (OS), and was calculated as 
the interval from the date of randomization until death 
from any cause or until the date of last follow-up. The 
secondary objectives included PFS and tumor response. 
PFS for first-line treatment was calculated from the 
date of randomization to the first observation of disease 
progression or death from any cause. Assessment of tumor 
response was performed with computed tomography (CT) 
scans using to Response Evaluation Criteria for Solid 
Tumors (RECIST) criteria. The written informed consent 
required for all patients before study entry also included 
translational research on tumor tissue.
Immunohistochemistry analysis was performed 
on 243 tumor samples of patients treated with first line 
capecitabine monotherapy (arm A) for whom sufficient 
tumor material was available. For the miRNA analysis 55 
patients treated with first line capecitabine monotherapy 
(arm A) were selected that had performance score 
0, normal serum LDH, received at least 3 cycles of 
capecitabine, received no prior adjuvant chemotherapy 
and for whom formalin-fixed paraffin-embedded (FFPE) 
material of the primary tumor as well as normal tissue was 
available. Supplemental Table 1, 2 contain the baseline 
characteristics of the patients included in the protein and 
miRNA detection analyses, respectively.
Immunohistochemistry on tissue microarrays
IHC analysis was performed on Tissue Micro Arrays 
(TMAs) containing primary tumor material. To assemble 
the arrays punches of 2 mm were taken from the FFPE 
primary tumor tissues. From each TMA, a 4 μm section 
was mounted on glass, de-paraffinised and re-hydrated.
The staining of Dicer was performed on a Ventana 
Benchmark XT autostainer with the XT ultraView DAB 
Kit (Ventana Medical Systems, Illkirch, France) using 
an antibody reacting with Dicer (Anti-DICER1, 1:75, 
Sigma–Aldrich, Hamburg, Germany). The slides were 
counterstained with Haematoxylin (Vector Laboratories). 
Different staining intensities were observed, and the 
scoring was performed as previously described [15]. 
Tumors were scored from 0 to 3, considering only the 
cytoplasmic area. Sections were evaluated three times, 
blinded to outcome data. The mean of all three values was 
then calculated and each sample was assigned to one of 
the four different IHC-staining categories (0–3).
For the staining of FXYD3, microwave antigen 
retrieval was performed using 10mM sodium citrate 
buffer (pH 6.0) for 10 minutes. After blocking endogenous 




 for 20 minutes, slides 
were incubated with rabbit anti-human polyclonal FXYD3 
antibody (Sigma-Aldrich, St. Louis, MO, USA, 1:200) 
overnight at 4°C. Subsequently, slides were incubated with 
Powervision Poly-HRP anti-Ms/Rb/Ra IgG (Immunologic, 
Duiven, The Netherlands) and developed using 
PowerDAB (Immunologic, Duiven, The Netherlands). 
Furthermore, slides were counterstained with hematoxylin 
(Vector Laboratories). 
The staining intensity of the cytoplasm was 
graded as weak (light brown) and strong (brown). All 
sections were evaluated blinded to outcome data by two 
independent observers. Discrepancies in scoring were 
evaluated by the two observers together to obtain an 
agreement.
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RNA extraction and miRNA assays
Total RNA was isolated from FFPE tissue using 
the RecoverAllTM Total Nucleic Acid Isolation Kit 
(Applied Biosystems, Foster city, USA). To ensure a 
high percentage of tumor cells, the tumor tissue sections 
were macro dissected. Matched normal mucosal RNA 
was obtained from the resection margins or at least 1 cm 
distance from the tumor. In brief, four tissue sections of 20 
µm were incubated with 100% xylene at 50°C to remove 
paraffin excess, followed by ethanol washes. Proteins 
were degraded by protease at 50° and 80°C. The RNA 
was extracted followed by nuclease digestion. Total RNA 
quantity and quality were determined using the Nanodrop 
26 ND-1000 spectrophotometer (Nanodrop Technologies 
Inc., Wilmington, USA).
The expression levels of miRNAs were determined 
by means of Taqman microRNA assays (Supplemental 
Table 4 contains a list with the assays), following the 
manufacture’s protocol (Applied Biosystems, Foster City, 
USA). First, cDNA was synthesized in triplicate from 
total RNA using the Human pool A Megaplex RT primers. 
Reverse transcriptase reactions were conducted using 66 
ng total RNA, 2.67 mM dNTPs, 75 U MultiScribe Reverse 
Transcriptase, 1x RT buffer, 2 U RNase inhibitor, 3 mM 
MgCl2 and 1x Taqman MicroRNA RT Primers (Applied 
Biosystems, Foster city, USA). The 7.5 µl reactions were 
incubated for 40 cycles for 2 minutes at 16°C, 1 minute at 
42°C and 1 second at 50°C followed by 5 minutes at 85°C 
for 5 minutes.
Pre-amplification was subsequently performed on 
2.5 µl of synthesized cDNA in a total reaction of 22.5 µl 
of 1x Taqman PreAmp Master Mix (Applied Biosystems, 
Foster city, USA). The reactions were incubated for 10 
minutes at 95°C, 2 minutes at 55°C, 2 minutes at 72°C, 
12 cycles of 15 second at 95°C and 4 minutes at 60°C, 10 
minutes at 99.9°C. 
The quantitative PCR was performed in a total 
mixture of 10 µl consisting of 0.1 µl RT product (1:4 
diluted from pre-amplified RT reaction), 1 x Taqman 
Universal PCR Master Mix (No AmpErase® UNG, 
Applied Biosystems, Foster City, USA) and 1 x the 
dedicated primer and probe mix. The reactions were 
incubated in a 96-well optical plate at 95°C for 10 
minutes, followed by 40 cycles at 95°C for 15 seconds 
and at 60°C for 1 minute. All reactions were carried out 
in duplicate in a 7500 Real Time PCR System (Applied 
Biosystems, Foster City, USA). Due to the plate set-up 
it was necessary to correct for inter plate variation by 
incorporating an IPC, in triplicate (data for stability testing 
not shown). The threshold cycle (Cq) was defined as the 
fractional cycle number at which the fluorescence passes 
the fixed threshold. Relative quantification of miRNA 
expression was calculated using the ΔCq method using 
GenEx software [32]. 
MiRNA target prediction
Lists of potential targets for miRNAs were created 
using the prediction algorithms TargetScan Release 6.2 
and MicroCosm Targets Version 5 [33, 34].
To identify genes that show loss of expression 
upon increased miRNA expression, data from the Cancer 
Genome Atlas (TCGA) was downloaded on the 25th of 
April 2013. The following filter settings were used to 
search in the data portal: Disease: COAD; Data Level: 3; 
Availability: Available. In total, we obtained IlluminaGA 
miRNASeq and RNASeq data for 177 tumor samples. 
The Spearman correlation and accompanying p-value was 
calculated for miR-143 expression and the expression of 
each mRNA. Genes with a negative rho and a p-value 
below 0.05 were considered putative target genes.
Overlaps between the lists of putative target genes 
were identified and visualized with a Venn diagram. Gene 
ontology analysis was performed using the web-based tool 
DAVID [35, 36].
Data analysis
The qPCR data was analyzed using the GenEx 
software (MultID v.5.3.4, Göteborg, Sweden). Application 
of NormFinder resulted in the use of miR-17, miR-19a, 
miR-20a and miR-24 as reference genes, as its combined 
use led to the lowest accumulated standard deviation. 
The suitability of these genes was confirmed by GeNorm 
analysis [37, 38]. The miRNA expression in tumor tissue 
is compared with the expression in normal tissue using the 
Wilcoxon signed rank test. The Kaplan-Meier method was 
used to make survival curves. The survival distributions 
were compared with the log-rank test. The distributions 
of clinico-pathological characteristics in different groups 
were compared with Fisher’s exact test or Wilcoxon rank 
sum test. Correction for multiple testing was performed 
with the Benjamini & Hochberg adjustment method. 
Multivariate survival analysis was performed with Cox 
proportional hazards regression. Statistical procedures 
were performed with R.
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